ARN News

Charleston, SC, Feb. 18, 2020— American Rheumatology Network (ARN) announces their partnership with Framework Management Information, Inc. (Framework) to develop AXCESS1, a new prescription access

Originally published in Biosimilar Development In the first installment of this four-part series, the members of the Biosimilar Development Editorial Board and friends discussed how

Originally published in Biosimilar Development As we close out another year of global biosimilar successes and twists and turns, it’s always important to take stock

Originally published in The Rheumatologist For patients responsible for out-of-pocket costs associated with high-deductible health insurance plans, the financial burden associated with rheumatologic care can

WASHINGTON, Nov. 12, 2019 /PRNewswire/ — Trio Health, a leading provider of real-world evidence, announced results from a study recently presented at the Annual Meeting of the

By Karen Ferguson, CEO of Discus Analytics, LLC. Discus Analytics and American Rheumatology Network (ARN) have announced a new partnership, designed to provide much-needed tools

Originally published on PRNewsWire.com WASHINGTON, Oct. 8, 2019 /PRNewswire/ — Trio Health, a leading provider of real-time data on real-world patients, today announced the creation of the

Originally published in Rheumatology Network The price of a medication can be a significant factor in poor adherence to treatment, and few other specialties have

by Colin Edgerton, MD Articularis Rheumatology Network is announcing a name change to American Rheumatology Network (ARN). This is a coming of age moment for

In episode three, Dr. Hausmann and his guests, Dr. Colin Edgerton, chair of the ACR’s Committee on Rheumatologic Care and Dr. Angus Worthing, chair of

Originally published in Rheumatology Network Better treatment outcomes have been documented in studies when physicians and pharmacists work together. During last year’s American College of

Originally published in Rheumatology Network Affordability is a leading cause of drug abandonment among rheumatology patients. Out-of-pocket costs can be substantial. For example, rheumatoid arthritis

ARN’s CEO Ray Waldrup is looking forward to exhibiting at the NORM 2019 conference in a couple of days! Stop by Booth 3 for more

Originally published in Biosimilar Development by Anna Rose Welch, Editor It never ceases to excite me when I hear that some organization, hospital, or clinic

Originally published in the The Center For Biosimilars Web Site It’s no secret that biosimilars that treat inflammatory diseases have struggled to gain ground in